Inhibitors of monocarboxylate transporters as host-directed antivirals against human adenoviruses
Antimicrobial Agents and Chemotherapy · 16.11.2026
DOI: 10.1128/aac.00425-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 16.11.2026. Verfasst von Sara Spjut und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science and Technology, Umeå University, Umeå, Sweden. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Familjen Erling-Perssons Stiftelse, Horizon 2020 European Commission, Kempestiftelserna.
Abstract (Originalsprache)
Human adenoviruses (HAdVs) are non-enveloped double-stranded DNA viruses that cause a wide range of typically mild, self-limiting infections in humans, but are associated with high morbidity and mortality in immunocompromised individuals. There are currently no approved antivirals specifically targeting HAdV infection. To identify novel anti-adenoviral compounds and host factors critical for infection, we screened a target-annotated library of 13,000 compounds, covering 1,763 known human targets, against HAdV type 11 in K562 cells. This screen yielded numerous anti-adenoviral compounds, many of which were kinase inhibitors, well known to also show antiviral activity. We instead focused on potent and selective inhibitors of monocarboxylate transporter 1 (MCT1) for further investigation. For 25 MCT1 inhibitors, antiviral activity correlated clearly with MCT1 inhibitory potency, indicating MCT1 inhibition as the likely mechanism. MCT1 exports lactate and is frequently overexpressed in cancers that rely on aerobic glycolysis; many viruses similarly reprogram host metabolism toward glycolysis, increasing intracellular lactate that must be effluxed. Unexpectedly, MCT1 inhibitors were ineffective in A549 cells due to compensatory activity of MCT4, as A549 cells express both MCT1 and MCT4, whereas K562 cells express only MCT1. A selective MCT4 inhibitor was inactive in both cell lines, suggesting that simultaneous inhibition of both transporters is required. Accordingly, combined MCT1 and MCT4 inhibition synergistically blocked HAdV infection in both transformed cell types and primary normal human bronchial epithelial cells. These findings underscore the importance of host cell metabolism in HAdV infection and identify MCTs as promising antiviral targets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science and Technology, Umeå University, Umeå, Sweden.
- Department of Clinical Microbiology, Faculty of Medicine, Umeå University, Umeå, Sweden.
- Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
- Molecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
- Institute of Technology, University of Tartu, Tartu, Estonia.
ORCID-Profile: Magnus Evander, Mikael Elofsson
Förderung
- Familjen Erling-Perssons Stiftelse
- Horizon 2020 European Commission
- Kempestiftelserna
Zitieren
APA
Spjut, S., Strand, M., Fitzek, M., Iyer, P., Preston, M., Smith, D. M., Davis, A. M., Freitas-Huhtamäki, A., Viru, L., Evander, M., & Elofsson, M. (2026). Inhibitors of monocarboxylate transporters as host-directed antivirals against human adenoviruses. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00425-26
Vancouver
Spjut S, Strand M, Fitzek M, Iyer P, Preston M, Smith DM, et al. Inhibitors of monocarboxylate transporters as host-directed antivirals against human adenoviruses. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00425-26
BibTeX
@article{Spjut2026,
author = {Spjut, Sara and Strand, Mårten and Fitzek, Martina and Iyer, Preeti and Preston, Marian and Smith, David M and Davis, Andrew M and Freitas-Huhtamäki, Amanda and Viru, Liane and Evander, Magnus and Elofsson, Mikael},
title = {Inhibitors of monocarboxylate transporters as host-directed antivirals against human adenoviruses},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00425-26}
}
EUVIMED